{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:42:54Z","timestamp":1760982174816},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1007\/s11940-003-0036-6","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T21:13:33Z","timestamp":1181078013000},"page":"299-308","source":"Crossref","is-referenced-by-count":9,"title":["Tourette\u2019s syndrome in children"],"prefix":"10.1007","volume":"5","author":[{"given":"James E.","family":"Swain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Leckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"36_CR1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association: In Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington DC: American Psychiatric Association; 1994.","edition":"edn 4"},{"key":"36_CR2","first-page":"43","volume-title":"Tourette Syndrome: Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care","author":"RA King","year":"1999","unstructured":"King RA, Leckman, Scahill L: Obsessive-compulsive disorder, anxiety, and depression. In Tourette Syndrome: Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. Edited by Leckman JF, Cohen DJ. New York: John Wiley and Sons; 1999:43\u201362."},{"key":"36_CR3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(02)11526-1","volume":"360","author":"JF Leckman","year":"2002","unstructured":"Leckman JF: Tourette\u2019s syndrome. Lancet 2002, 360:1577\u20131586. This recent review contains the most up-to-date model of the neural substrates of habit formation and tics, schematically diagramed and discussed.","journal-title":"Lancet"},{"key":"36_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1542\/peds.102.1.14","volume":"102","author":"JF Leckman","year":"1998","unstructured":"Leckman JF, Zhang H, Vitale A, et al.: Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998, 102:14\u201319.","journal-title":"Pediatrics"},{"key":"36_CR5","first-page":"526","volume-title":"Pediatric Psychopharmacology","author":"RA King","year":"2002","unstructured":"King RA, Scahill L, Lombroso PJ, Leckman JF: Tourette\u2019s syndrome and other tic disorders, In Pediatric Psychopharmacology. Edited by Scahill L, King RA, Leckman JF. New York: Oxford; 2002:526\u2013542."},{"key":"36_CR6","first-page":"415","volume-title":"Tourette Syndrome: Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care","author":"DB Findley","year":"1999","unstructured":"Findley DB, King RA, Cohen DJ, Leckman JF: Yale Child Study Center Tourette\u2019s syndrome obsessive-compulsive disorder specialty clinic symptom questionnaire. In Tourette Syndrome: Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. Edited by Leckman JF, Cohen DJ. New York: John Wiley and Sons; 1999:415\u2013454."},{"key":"36_CR7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","volume":"58","author":"The Tourette\u2019s Syndrome Study Group","year":"2002","unstructured":"The Tourette\u2019s Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002, 58:527\u2013536. This is a key, multicenter, randomized, double-blind, placebocontrolled study showing efficacy of clonidine for tic reduction in children with ADHD.","journal-title":"Neurology"},{"key":"36_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/jnnp.70.5.666","volume":"70","author":"TB Babel","year":"2001","unstructured":"Babel TB, Warnke PC, Ostertag CB: Immediate and long term outcome after infrathalamic and thalamic lesioning for intractable Tourette\u2019s syndrome. J Neurol Neurosurg Psychiatry 2001, 70:666\u2013671.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"36_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S0140-6736(98)05964-9","volume":"353","author":"W Vandewalle","year":"1999","unstructured":"Vandewalle W, VanderLinden C, Groenewegen HJ, Caemaert J: Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet 1999, 353:724.","journal-title":"Lancet"},{"key":"36_CR10","first-page":"225","volume-title":"Tourette Syndrome and Associated Disorders","author":"MS George","year":"2001","unstructured":"George MS, Sallee FR, Nahas Z, et al.: Transcranial magnetic stimulation (TMS) as a research tool. In Tourette Syndrome and Associated Disorders. Edited by Leckman JF, Cohen DJ. Philadelphia: Lippincott Williams & Wilkins; 2001:225\u2013235. This paper reviews the exciting new experimental modality of transcranial magnetic stimulation."},{"key":"36_CR11","first-page":"338","volume-title":"Tourette Syndrome: Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care","author":"RA King","year":"1999","unstructured":"King RA, Scahill L, Findley D, Cohen DJ: Psychosocial and behavioral treatments. In Tourette Syndrome: Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. Edited by Leckman JF, Cohen DJ. New York: John Wiley and Sons; 1999:338\u2013359."},{"key":"36_CR12","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","volume":"158","author":"L Scahill","year":"2001","unstructured":"Scahill L, Chappell PB, Kim YS, et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067\u20131074. This is the key, placebo-controlled double-blind parallel study showing efficacy of guanfacine for tic reduction.","journal-title":"Am J Psychiatry"},{"key":"36_CR13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpsyc.1991.01810280040006","volume":"48","author":"JF Leckman","year":"1991","unstructured":"Leckman JF, Hardin MT, Riddle MA, et al.: Clonidine Treatment of Gilles de la Tourette\u2019s syndrome. Ach Gen Psychiatry 1991, 48:324\u2013328.","journal-title":"Ach Gen Psychiatry"},{"key":"36_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4088\/JCP.v62n0111","volume":"62","author":"R Bruggeman","year":"2001","unstructured":"Bruggeman R, van der Linden C, Buitelaar JK, et al.: Risperidone versus pimozide in Tourette\u2019s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50\u201356.","journal-title":"J Clin Psychiatry"},{"key":"36_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","volume":"41","author":"GR Gaffney","year":"2002","unstructured":"Gaffney GR, Perry PJ, Lund BC, et al.: Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s syndrome. J Am Amer Acad Child Adolesc Psychiatry 2002, 41:330\u2013336.","journal-title":"J Am Amer Acad Child Adolesc Psychiatry"},{"key":"36_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/archneur.60.8.1130","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, et al.: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130\u20131135. This is the key, placebo-controlled, double-blind, parallel study showing efficacy of risperidone for tic reduction.","journal-title":"Neurology"},{"key":"36_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","volume":"15","author":"M Stamenkovic","year":"2000","unstructured":"Stamenkovic M, Schindle SD, Aschauser HN, et al.: Effective open-label treatment of Tourette disorder with olanzapine. Int Clin Psychopharmacol 2000, 15:23\u201328.","journal-title":"Int Clin Psychopharmacol"},{"key":"36_CR18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"CL Budman","year":"2001","unstructured":"Budman CL, Gayer A, Lesser M, et al.: An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder. J Clin Psychiatry 2001, 62:290\u2013294.","journal-title":"J Clin Psychiatry"},{"key":"36_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s004150070173","volume":"247","author":"M Onofrj","year":"2000","unstructured":"Onofrj M, Paci C, D\u2019Andrematteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double blind cross over study vs. low-dose pimozide. J Neurol 2000, 247:443\u2013446.","journal-title":"J Neurol"},{"key":"36_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"FR Sallee","year":"2000","unstructured":"Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette\u2019s disorder. J Am Amer Acad Child Adolesc Psychiatry 2000, 39:292\u2013299. This is the key, placebo-controlled parallel study showing efficacy of ziprasidone for tic reduction.","journal-title":"J Am Amer Acad Child Adolesc Psychiatry"},{"key":"36_CR21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro AK, Fulop G, et al.: Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatry 1989, 46:722\u2013730.","journal-title":"Arch Gen Psychiatry"},{"key":"36_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/00004583-198403000-00007","volume":"23","author":"AK Shapiro","year":"1984","unstructured":"Shapiro AK, Shapiro E: Controlled study of pimozide vs. placebo in Tourette\u2019s syndrome. J Am Acad Child Adolesc Psychiatry 1984, 23:161\u2013173.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"36_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00449911","volume":"237","author":"CH Eggers","year":"1988","unstructured":"Eggers CH, Rothenberger A, Berghaus U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988, 237:223\u2013229.","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"36_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00002826-199006000-00005","volume":"13","author":"MM Roberston","year":"1990","unstructured":"Roberston MM, Schneiden V, Lees AJ: Management of Gilles de la Tourette syndrome using sulipride. Clin Neuropsychopharmacol 1990, 13:229\u2013235.","journal-title":"Clin Neuropsychopharmacol"},{"key":"36_CR25","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.54.6.1310","volume":"54","author":"DL Gilbert","year":"2000","unstructured":"Gilbert DL, Sethuraman G, Sine L, et al.: Tourette\u2019s syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000, 54:1310\u20131315.","journal-title":"Neurology"},{"key":"36_CR26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","volume":"38","author":"J Jankovic","year":"1988","unstructured":"Jankovic J, Orman J: Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988, 38:391\u2013394.","journal-title":"Neurology"},{"key":"36_CR27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358\u2013362.","journal-title":"Neurology"},{"key":"36_CR28","first-page":"245","volume":"58","author":"CG Goetz","year":"1992","unstructured":"Goetz CG: Clonidine and clonazpam in Tourettes syndrome. Adv Neurol 1992, 58:245\u2013251.","journal-title":"Adv Neurol"},{"key":"36_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/00004714-199908000-00019","volume":"19","author":"SP Hoopes","year":"1999","unstructured":"Hoopes SP: Donepezil for Tourette\u2019s disorder and ADHD. J Clin Psychopharmacol 1999, 19:381\u2013382.","journal-title":"J Clin Psychopharmacol"},{"key":"36_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00002826-199002000-00008","volume":"13","author":"F Michaeli","year":"1990","unstructured":"Michaeli F, Gatto M, Lekuniec E, et al.: Treatment of Tourette\u2019s syndrome with calcium antagonists. Clin Neuropsychopharmacol 1990, 13:77\u201383.","journal-title":"Clin Neuropsychopharmacol"},{"key":"36_CR31","first-page":"360","volume":"45","author":"JA Goldstein","year":"1984","unstructured":"Goldstein JA: Nifedipine treatment of Tourette\u2019s syndrome. J Clin Psychiatry 1984, 45:360.","journal-title":"J Clin Psychiatry"},{"key":"36_CR32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1600-0447.1985.tb02629.x","volume":"72","author":"R Berg","year":"1985","unstructured":"Berg R: A case of Tourette\u2019s syndrome treated with nifedipine. Acta Psychiatr Scand 1985, 72:400\u2013401.","journal-title":"Acta Psychiatr Scand"},{"key":"36_CR33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archneur.1993.00540030052014","volume":"50","author":"J Jankovic","year":"1993","unstructured":"Jankovic J: Deprenyl in attention deficit associated with Tourette\u2019s syndrome. Arch Neurol 1993, 50:286\u2013288.","journal-title":"Arch Neurol"},{"key":"36_CR34","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1212\/WNL.46.4.965","volume":"46","author":"A Feigin","year":"1996","unstructured":"Feigin A, Kurlan R, McDermott MP, et al.: A controlled trial of deprenyl in children with Tourette\u2019s syndrome and attention deficit hyperactivity disorder. Neurology 1996, 46:965\u2013968.","journal-title":"Neurology"},{"key":"36_CR35","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H","volume":"15","author":"JK Black","year":"2000","unstructured":"Black JK, Mink JW: Response to levodopa challenge in Tourette\u2019s syndrome. Mov Disord 2000, 15:1194\u20131198.","journal-title":"Mov Disord"},{"key":"36_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00004850-199911000-00008","volume":"14","author":"P Toren","year":"1999","unstructured":"Toren P, Laor N, Cohen DJ, et al.: Odansetron treatment in patients with Tourette\u2019s syndrome. Int Clin Psychopharmacol 1999, 14:373\u2013376.","journal-title":"Int Clin Psychopharmacol"},{"key":"36_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ana.410300105","volume":"30","author":"R Kurlan","year":"1991","unstructured":"Kurlan R, Majumdar L, Deeley C, et al.: A controlled trial of propoxyphene and naltrexone in patients with Tourette\u2019s syndrome. Ann Neurol 1991, 30:19\u201323.","journal-title":"Ann Neurol"},{"key":"36_CR38","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00004714-199808000-00013","volume":"18","author":"BS Peterson","year":"1998","unstructured":"Peterson BS, Zhang H, Anderson GM, Leckman JF: A double-blind placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette\u2019s syndrome. J Clin Psychopharmacol 1998, 18:324\u2013331.","journal-title":"J Clin Psychopharmacol"},{"key":"36_CR39","first-page":"710","volume":"44","author":"M Izmir","year":"1999","unstructured":"Izmir M, Dursun SM: Cyproterone acetate treatment of Tourette\u2019s syndrome. Can J Psychiatry 1999, 44:710\u2013711.","journal-title":"Can J Psychiatry"},{"key":"36_CR40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.158.6.968","volume":"158","author":"FS Abuzzahab","year":"2001","unstructured":"Abuzzahab FS, Brown VL: Control of Tourette\u2019s syndrome with topiramate. Am J Psychiatry 2001, 158:968.","journal-title":"Am J Psychiatry"},{"key":"36_CR41","first-page":"75","volume":"7","author":"L Scahill","year":"1997","unstructured":"Scahill L, Riddle MA, King RA, et al.: Fluoxetine has no marked effect on tic symptoms in patients with Tourette\u2019s syndrome: a double-blind placebo-controlled study. J Am Amer Acad Child Adolesc Psychiatry 1997, 7:75\u201385.","journal-title":"J Am Amer Acad Child Adolesc Psychiatry"},{"key":"36_CR42","first-page":"193","volume":"3","author":"MA Riddle","year":"1991","unstructured":"Riddle MA, King RA, Hardin MT, et al.: Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1991, 3:193\u2013198.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"36_CR43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/088307389901400508","volume":"14","author":"Y Awaad","year":"1999","unstructured":"Awaad Y: Tics in Tourette syndrome: new treatment options. J Child Neurol 1999, 14:316\u2013319.","journal-title":"J Child Neurol"},{"key":"36_CR44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1212\/WNL.56.5.599","volume":"56","author":"HS Singer","year":"2001","unstructured":"Singer HS, Wendlandt J, Krieger M, Giuliano J: Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599\u2013604.","journal-title":"Neurology"},{"key":"36_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0753-3322(89)90186-8","volume":"43","author":"PR Sanberg","year":"1989","unstructured":"Sanberg PR, McConville BJ, Fogelson HM, et al.: Nicotine potentiates the effects of haloperidol in animals and in patients with tic disorders and attention deficit-hyperactivity disorder. Biomed Pharmacother 1989, 43:19\u201323.","journal-title":"Biomed Pharmacother"},{"key":"36_CR46","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/0006-3223(92)90315-Q","volume":"15","author":"BJ McConville","year":"1992","unstructured":"McConville BJ, Sandberg PR, Fogelson MH, et al.: The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette\u2019s disorder. Biol Psychiatry 1992:15:832\u2013840.","journal-title":"Biol Psychiatry"},{"key":"36_CR47","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/00004583-199612000-00015","volume":"35","author":"AA Silver","year":"1996","unstructured":"Silver AA, Shytle RD, Philipp MK, Sanberg PR: Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette\u2019s syndrome. J Am Acad Child Adolesc Psychiatry 1996, 35:1631\u20131636.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"36_CR48","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4088\/JCP.v62n0908","volume":"62","author":"AA Silver","year":"2001","unstructured":"Silver AA, Shytle RD, Philipp MK, et al.: Transdermal nicotine and haloperidol in Tourette\u2019s disorder: a double-blind placebo controlled study. J Clin Psychiatry 2001, 62:707\u2013714.","journal-title":"J Clin Psychiatry"},{"key":"36_CR49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/cap.2000.10.59","volume":"10","author":"AA Silver","year":"2000","unstructured":"Silver AA, Shytle RD, Sanberg PR: Mecamylamine in Tourette\u2019s syndrome: a two-year case study. J Child Adolesc Psychopharmacol 2000, 10:59\u201368.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"36_CR50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(05)60822-7","volume":"352","author":"PR Sanberg","year":"1998","unstructured":"Sanberg PR, Shytle RD, Silver AA: Treatment of Tourette syndrome with mecamylamine. Lancet 1998, 352:705\u2013706.","journal-title":"Lancet"},{"key":"36_CR51","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/00004583-200109000-00020","volume":"40","author":"AA Silver","year":"2001","unstructured":"Silver AA, Shytle RD, Sheehan KH, et al.: Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:1103\u20131110.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"36_CR52","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","volume":"57","author":"CH Kwak","year":"2000","unstructured":"Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190\u20131193.","journal-title":"Arch Neurol"},{"key":"36_CR53","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Marras","year":"2001","unstructured":"Marras C, Andrewa D, Sime E, Lang AE: Botulinum toxin for simple motor tics: a randomized, doubleblind, controlled clinical trial. Neurology 2001, 56:605\u2013610. This is the one randomized, double-blind, placebo-controlled crossover study showing efficacy of botulinum toxin for tic reduction.","journal-title":"Neurology"},{"key":"36_CR54","first-page":"319","volume-title":"Tourette Syndrome and Associated Disorders","author":"J Piacentini","year":"2001","unstructured":"Piacentini J, Chang S: Behavioral treatments for Tourette syndrome in tic disorders: state of the art. In Tourette Syndrome and Associated Disorders. Edited by Leckman JF, Cohen DJ. Philadelphia: Lippincott Williams & Wilkins; 2001:319\u2013331."},{"key":"36_CR55","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0887-8994(00)00131-4","volume":"22","author":"HS Singer","year":"2000","unstructured":"Singer HS, Giuliano JD, Zimmerman AM, et al.: Infection: a stimulus for tic disorders. Pediatr Neurol 2000, 22:380\u2013383.","journal-title":"Pediatr Neurol"},{"key":"36_CR56","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(98)12297-3","volume":"354","author":"J Perlmutter","year":"1999","unstructured":"Perlmutter J, Leitman SF, Garvey MA, et al.: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153\u20131158.","journal-title":"Lancet"},{"key":"36_CR57","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0006-3223(99)00020-7","volume":"45","author":"MA Garvey","year":"1999","unstructured":"Garvey MA, Perlmutter J, Allen AJ, et al.: A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry 1999, 45:1564\u20131571.","journal-title":"Biol Psychiatry"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-003-0036-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-003-0036-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-003-0036-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-003-0036-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:33:03Z","timestamp":1652614383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-003-0036-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1007\/s11940-003-0036-6","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}